Search

Find exactly what you’re looking for.
Search

Service
Location
Showing 1-20 of 30 results

Cultivating A Trade Secret Mindset: Risk Mitigation, Reasonable Measures, and Internal Awareness To harness and optimize Trade Secret IP value, organizations must foster a robust trade secret risk mitigation mindset. In this enlightening session, the panel will explore three pivotal pillars: risk...

Please join Saul Ewing LLP and ARIAS U.S. for a half-day educational workshop and networking opportunity. For event inquiries, please contact info@arias-us.org. Panel Discussions Primer on Mass Tort Bankruptcies and Insolvencies The Current Lay of the Land, Including Scottish Re, Arrowood Crossroads...

Intellectual Property 101 / Copyrights, Patents, and Trademarks…Oh My! Thomas Edison. Henry Ford. Steve Jobs. These three household names revolutionized modern society through the protections afforded to their intellectual property by U.S. patent laws. Traditionally a copyright attaches when the...

Maryland’s intermediate court created new and binding precedent for cases related to misappropriation of trade secrets under the Maryland Uniform Trade Secrets Act (“MUTSA”). In the reported opinion of Ingram, et al. v. Cantwell-Cleary Co., Inc., the Appellate Court of Maryland held that customer...

"Innovation continues across industries at a rapid pace. Many companies maintain highly valuable trade secrets and private data that provide them with a competitive market advantage. The rapidly evolving technological landscape, however, leads to new and more sophisticated threats to a company’s...

January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

The Fundamentals of Arbitration Are you dealing with a dispute and debating whether to resolve it through arbitration pursuant to an arbitration provision in the subject agreement? Are you considering adding an arbitration provision to your standard contracts? This webinar will provide you with the...

For More Information
Contact us